Vivus Inc., of Mountain View, Calif., reported third-quarter revenue of $13.4 million compared to $24.9 million in the third quarter of 2015, with net revenue from obesity drug Qsymia (phentermine, topiramate) totaling $12.3 million and $14 million for the third quarters of 2016 and 2015, respectively. The amounts represent about 109,000 and 146,000 prescriptions for the third quarters of 2016 and 2015, respectively, of which about 64.2 percent and 62.9 percent represent either a free or discounted offer. Net revenue per prescription, excluding free trial offers, was about $125 and $117 for the third quarters of 2016 and 2015 respectively, the company said. Vivus ended the quarter with about $283.6 million on its balance sheet. Shares of Vivus (NASDAQ:VVUS) closed flat Thursday at $1.09.